Lv11
90 积分 2022-08-23 加入
Metabolism, pharmacokinetics and excretion of a novel hypoxia activated cytotoxic prodrug, TH-302, in rats
2小时前
待确认
Dual CTLA‐4 and PD‐1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first‐in‐human, dose‐escalation, and dose‐expansion study
27天前
已完结
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
1个月前
已完结
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
1个月前
已完结
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
1个月前
已完结
Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy
1个月前
已完结
Norcantharidin toxicity profile: an in vivo murine study
2个月前
已完结
Modified norcantharidins
2个月前
已完结
Synthesis and biological evaluation of norcantharidin analogues: Towards PP1 selectivity
2个月前
已完结
The radiotherapy-sensitization effect of cantharidin: Mechanisms involving cell cycle regulation, enhanced DNA damage, and inhibited DNA damage repair
2个月前
已完结
皖公网安备34019202002308
